Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 10/2023

22-09-2023 | Colchicine | Drug Reactions and Interactions

Prescribe colchicine with care and be aware of colchicine drug interactions

Authors: Amy Zhuang-Yan, Connie Kang

Published in: Drugs & Therapy Perspectives | Issue 10/2023

Login to get access

Abstract

Colchicine has multiple anti-inflammatory properties and is used for a variety of disorders. As the use of colchicine expands from its approved uses (e.g. gout) to various off-label indications (e.g. pericarditis), the risk for drug–drug interactions (DDIs) to occur with colchicine increases. Colchicine is a substrate for cytochrome P450 3A4 (CYP3A4) and permeability glycoprotein (P-gp) and, when used concurrently with other CYP3A4 and/or P-gp inhibitors, can lead to life-threatening outcomes. This article summarises the risks associated with colchicine use, mechanisms behind adverse DDIs and various management options to minimise patient harm from colchicine DDIs.
Literature
1.
Şen S, Karahan E, Büyükulaş C, et al. Colchicine for cardiovascular therapy: a drug interaction perspective and a safety meta-analysis. Anatol J Cardiol. 2021;25(11):753–61. CrossRefPubMedPubMedCentral
2.
Hansten PD, Tan MS, Horn JR, et al. Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management. Drug Saf. 2023;46(3):223–42. CrossRefPubMed
3.
Dixon DL, Patel J, Spence R, et al. Select drug-drug interactions with colchicine and cardiovascular medications: a review. Am Heart J. 2022;252:42–50. CrossRefPubMed
4.
Niel E, Scherrmann JM. Colchicine today. Jt Bone. Spine. 2006;73:672–8.
5.
Finkelstein Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol. 2010;48:407–14. CrossRef
6.
Villa Zapata L, Hansten PD, Horn JR, et al. Evidence of clinically meaningful drug–drug interaction with concomitant use of colchicine and clarithromycin. Drug Saf. 2020;43:661–8. CrossRefPubMed
7.
Berl T, Wilner KD, Gardner M, et al. Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol. 1995;6:242–7. CrossRefPubMed
8.
Su YC, Wu CC. Colchicine-induced acute neuromyopathy in a patient using concomitant fluconazole: case report and literature review. Drug Saf Case Rep. 2015;2:16. CrossRefPubMedPubMedCentral
9.
Robinson PC, Terkeltaub R, Pillinger MH, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2022;135(1):32–8. CrossRefPubMed
10.
Schwier NC, Cornelio CK, Boylan PM. A systematic review of the drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy. 2022;42(4):320–33. CrossRefPubMed
11.
Hung IFN, Wu AKL, Cheng VCC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis. 2005;41:291–300. CrossRefPubMed
Metadata
Title
Prescribe colchicine with care and be aware of colchicine drug interactions
Authors
Amy Zhuang-Yan
Connie Kang
Publication date
22-09-2023
Publisher
Springer International Publishing
Keyword
Colchicine
Published in
Drugs & Therapy Perspectives / Issue 10/2023
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-023-01024-x

Other articles of this Issue 10/2023

Drugs & Therapy Perspectives 10/2023 Go to the issue

First reports of adverse drug reactions

First reports of adverse drug reactions

Practical Issues and Updates

Treat functional constipation in children with conventional options first and consider alternatives if needed

Drug Reactions and Interactions

Nails blue? Don’t be sad, the cause may be discoverable

Commentary

Addressing the opioid epidemic in Pakistan: urgent need for opioid stewardship and comprehensive solutions

Adis Drug Q&A

RBX2660 (REBYOTA®) in preventing recurrence of Clostridioides difficile infection: a profile of its use in the USA